CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates

Group 1: Earnings Performance - CRISPR Therapeutics reported a quarterly loss of $1.29 per share, better than the Zacks Consensus Estimate of a loss of $1.47, and an improvement from a loss of $1.49 per share a year ago, representing an earnings surprise of +12.24% [1] - The company posted revenues of $0.89 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 86.45%, compared to year-ago revenues of $0.52 million [2] - Over the last four quarters, CRISPR Therapeutics has surpassed consensus EPS estimates three times [2] Group 2: Stock Performance and Outlook - CRISPR Therapeutics shares have increased approximately 42.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 6.1% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is -$1.35 on revenues of $8.89 million, and -$5.61 on revenues of $41.42 million for the current fiscal year [7] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5] - The unfavorable estimate revisions trend prior to the earnings release resulted in a Zacks Rank 5 (Strong Sell) for CRISPR Therapeutics, suggesting expected underperformance in the near future [6]